The development of a radiotheranostic for castrate–resistant prostate cancer (CRPC) is a particularly noteworthy example, wherein a small molecule for the prostate–specific membrane antigen (PSMA–617) is combined with a therapeutic radioisotope (177Lutetium) to specifically target prostate cancer cells (1). This evidence concerns the gene FOLH1 and prostate carcinoma.